Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sargramostim + thalidomide + docetaxel
- Development stage
- Discontinued
- Lead developer
- Partner Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
A three-drug investigational oncology regimen combining sargramostim, thalidomide, and docetaxel. Sargramostim is recombinant human granulocyte-macrophage colony-stimulating factor that activates and matures dendritic cells and enhances antitumor immune responses. Thalidomide is an immunomodulatory and antiangiogenic small molecule that inhibits pro-angiogenic signaling and modulates T cell and NK cell function. Docetaxel is a taxane chemotherapeutic that stabilizes microtubules to inhibit mitosis and induce apoptosis, with additional antiangiogenic effects reported. The combination has been explored primarily in prostate cancer to augment chemotherapy with immunostimulation and antiangiogenesis; early-phase work studied sargramostim plus thalidomide and separately thalidomide plus docetaxel, with DrugBank listing a terminated phase 2 trial including all three components in prostate cancer.
- Other names
- GM-CSF + thalidomide + docetaxel
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TUBB (Tubulin (alpha and beta subunits))TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on sargramostim + thalidomide + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sargramostim + thalidomide + docetaxel.